-
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Clinical ImmunologyHerold KC, Gitelman S, Greenbaum CJ, Puck J, Hagopian WA, Gottlieb PA, Sayre PH, Bianchine PJ, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA, Immune Tolerance Network ITN007AI Study Group. -
The effect of age on insulin sensitivity and insulin secretion in first-degree relatives of type 1 diabetic patients: a population analysis.
The Journal of Clinical Endocrinology and MetabolismMa X, Becker D, Arena VC, Vicini P, Greenbaum CJ -
Type 1 Diabetes TrialNet--an international collaborative clinical trials network.
Annals of the New York Academy of SciencesSkyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L, Type 1 Diabetes TrialNet Study Group. -
The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells.
Journal of ImmunologySchneider A, Rieck M, Sanda S, Pihoker C, Greenbaum CJ, Buckner JH -
Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes.
Diabetes CareGreenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H, Type 1 Diabetes Trial Net Research Group., European C-Peptide Trial Study Group. -
CD4+ T cells from type 1 diabetic and healthy subjects exhibit different thresholds of activation to a naturally processed proinsulin epitope.
Journal of AutoimmunityYang J, Danke N, Roti M, Huston L, Greenbaum CJ, Pihoker C, James EA, Kwok WW -
Type 1 diabetes mellitus: primary, secondary, and tertiary prevention.
The Mount Sinai Journal of Medicine, New YorkBollyky J, Sanda S, Greenbaum CJ -
Health-related quality of life of children and adolescents with type 1 or type 2 diabetes mellitus: SEARCH for Diabetes in Youth Study.
Archives of Pediatrics & Adolescent MedicineNaughton MJ, Ruggiero AM, Lawrence JM, Imperatore G, Klingensmith GJ, Waitzfelder B, McKeown RE, Standiford DA, Liese AD, Loots B, SEARCH for Diabetes in Youth Study Group., Greenbaum CJ -
Standardization of C-peptide measurements.
Clinical ChemistryLittle RR, Rohlfing CL, Tennill AL, Madsen RW, Polonsky KS, Myers GL, Greenbaum CJ, Palmer JP, Rogatsky E, Stein DT -
Use of oral glucose minimal model-derived index of insulin sensitivity in subjects with early type 1 diabetes mellitus.
Metabolism: Clinical and ExperimentalKrudys KM, Greenbaum CJ, Pihoker C, Vicini P -
A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1.
Diabetes CareSosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson D, Lachin JM, Skyler JS, Diabetes Prevention Trial-Type 1 Study Group. -
Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes.
Journal of ImmunologyRieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum CJ, Concannon P, Buckner JH -
Role of insulin resistance in predicting progression to type 1 diabetes.
Diabetes CareXu P, Cuthbertson D, Greenbaum CJ, Palmer JP, Krischer JP, Diabetes Prevention Trial Type 1 Study Group. -
Editorial: The role of glucagon in postprandial hyperglycemia--the jury's still out.
The Journal of Clinical Endocrinology and MetabolismBollyky J, Greenbaum CJ -
International comparison of C-peptide measurements.
Clinical ChemistryWiedmeyer HM, Polonsky KS, Myers GL, Little RR, Greenbaum CJ, Goldstein DE, Palmer JP
